文献速递鼻科

全身性贝伐珠单抗对遗传性出血性毛细血管扩张症鼻出血相关结局的影响:系统评价与Meta分析

The Effect of Systemic Bevacizumab on Epistaxis-Related Outcomes in Hereditary Hemorrhagic Telangiectasia: A Systematic Review and Meta-Analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-03-17

该系统评价与Meta分析纳入10项研究共225例患者,评估全身性贝伐珠单抗治疗遗传性出血性毛细血管扩张症(HHT)相关鼻出血的效果。结果显示治疗后平均ESS降低-3.33(95%CI -3.62至-3.03),平均Hb升高2.38 g/dL(95%CI 1.45-3.30),所有队列研究均发现红细胞和铁输注需求显著减少,最常见不良事件为高血压。作者认为需足够效能的进一步研究。

要点

  • 全身性贝伐珠单抗与HHT鼻出血ESS显著降低-3.33(95%CI -3.62至-3.03)相关。
  • 治疗后平均Hb较治疗前显著升高2.38 g/dL(95%CI 1.45-3.30)。
  • 所有队列研究均报告治疗后红细胞和铁输注需求显著减少,最常见不良事件为高血压。

核心结论

  • 全身性贝伐珠单抗与HHT相关鼻出血的严重程度、血红蛋白及输注需求显著改善相关。
  • 需要足够效能的进一步研究来强化该发现,患者选择标准、标准化维持剂量及长期治疗数据有待进一步研究。

研究设计与样本

  • 遵循PRISMA指南开展系统评价与Meta分析,检索三个数据库截至2024年9月。
  • 纳入评估全身性贝伐珠单抗对HHT鼻出血结局影响的研究,共10项研究、225例患者。
  • 采用随机效应模型对ESS变化(ΔESS)和血红蛋白变化(ΔHb)进行Meta分析,并使用Joanne Briggs研究所批判性评价工具评估文献质量。

主要发现

  • 与治疗前相比,治疗后平均ESS降低-3.33(95%CI -3.62至-3.03),差异有统计学意义。
  • 与治疗前相比,治疗后平均Hb升高2.38 g/dL(95%CI 1.45-3.30),差异有统计学意义。
  • 所有队列研究均发现全身性贝伐珠单抗治疗后红细胞和铁输注显著减少。
  • 全身性贝伐珠单抗最常报告的不良事件为高血压。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要足够效能的进一步研究来强化该发现。
  • 患者选择标准、标准化维持剂量及长期治疗数据有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evidence-based recommendation for the use of systemic bevacizumab to treat refractory epistaxis in hereditary hemorrhagic telangiectasia (HHT) is based on limited and historical data. An updated synthesis of the available literature is warranted. METHODS: A systematic review and meta-analysis were conducted using PRISMA guidelines to evaluate the use of systemic bevacizumab for HHT-related epistaxis. A search was conducted using three databases up to September 2024 for studies assessing the effect of systemic bevacizumab use on epistaxis outcomes in HHT. Outcome measures included epistaxis severity score (ESS), hemoglobin, red blood cell (RBC), and iron transfusion requirements and adverse effects. Random effects meta-analysis was performed for change in ESS (ΔESS) and change in hemoglobin (ΔHb). Literature quality was assessed using the Joanne Briggs Institute critical appraisal tools. RESULTS: A total of 10 studies with 225 total patients were included. Systemic bevacizumab was associated with a significant posttreatment reduction in mean ESS of -3.33 (95% CI -3.62 to -3.03) and a significant increase in mean Hb of 2.38 g/dL (95% CI 1.45-3.30) compared to pretreatment. All cohort studies found a significant reduction in RBC and iron transfusions following systemic bevacizumab treatment. The most frequently reported adverse effect of systemic bevacizumab was hypertension. CONCLUSION: Systemic bevacizumab is associated with significant improvements in epistaxis severity, hemoglobin, and transfusion requirements in HHT-related epistaxis. Adequately powered studies are required to strengthen this finding. Patient selection criteria, standardized maintenance dosing, and long-term treatment data require further study.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Li W, Bai J, Symons A, et al. The Effect of Systemic Bevacizumab on Epistaxis-Related Outcomes in Hereditary Hemorrhagic Telangiectasia: A Systematic Review and Meta-Analysis. Int Forum Allergy Rhinol. 2025. PMID: 40095741. doi:10.1002/alr.23566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。